What cell-cultured milk is and how it differs from other dairy alternatives
Cell-cultured milk is milk, or a set of milk components, made by mammary epithelial cells grown outside an animal. The cells are expanded in a medium, moved into conditions that trigger lactation-like secretion, and the secreted proteins, lipids and sugars are harvested and processed into a dairy ingredient or a milk-like beverage.
It is one of two routes to animal-free milk. A 2025 review separates the bottom-up approach, which builds milk from individual recombinant components, from the top-down approach, which cultivates mammary cells. Precision fermentation sits between the two, because microbes make single proteins that are then recombined with fats and sugars.
The top-down route has a structural advantage. Culturing mammary epithelial cells most closely mimics natural lactation and potentially yields the most complete milk-like fluid, with naturally assembled structures such as the milk fat globule membrane. Replicating that membrane is hard for both bottom-up and top-down approaches, and structural accuracy is a formidable barrier.
Milk itself is complex. Bovine milk contains about 3.4 percent protein, with casein and whey in a ratio of 82 to 18, plus fat, lactose and minerals, while human milk has about 1.0 percent protein with a 40 to 60 ratio. Any cell-cultured milk has to be judged against that benchmark, for both nutrition and function.
Mammary cells, hormones and production
Production relies on hormone signals. A 2026 study of bovine mammary epithelial cells describes progesterone as promoting proliferation and alveolar structures, while prolactin induces milk secretory differentiation. In the experiments, cells grew to about 80 percent confluence and were then differentiated for five days with prolactin at 1,000 ng per mL or progesterone at 2,500 ng per mL.
Prolactin is the cost problem. The study calls the high price of prolactin a major limitation, and cites an earlier estimate of 4,417 US dollars per litre for alpha-casein and 574 dollars per litre for triglycerides in cultured mammary cells. The authors tested progesterone plus an MMP-2 and MMP-9 inhibitor as a cheaper route.
Other platforms aim at structure. A 2026 paper describes a mammary gland-on-a-chip with a medium channel, a porous hydrogel layer and microchambers for culturing mammary epithelial cells. The chip supports tight-junction formation and active secretion of milk components such as lactotransferrin and triglycerides, and upregulated genes for beta-casein, lactose and fat synthesis.
Scale is the unresolved challenge. A review estimates that media costs typically make up 60 to 75 percent of total production costs across bioreactor types, and that energy needs rise with scale. Cell-based milk therefore faces the same economics as other cellular agriculture, with cost per litre far above conventional dairy.
Cell-cultured milk costs and economics
The numbers explain why the field is early. A review contrasts conventional dairy protein at 15 to 25 dollars per kilogram with 210 to 310 dollars per kilogram for precision fermentation proteins, the cheaper of the two novel routes. Cell-based milk components estimated at thousands of dollars per litre are further from price parity.
Funding has been substantial but is not a substitute for unit economics. A review reports more than 800 million US dollars in venture capital committed since 2022 to companies developing precision fermentation and cellular agriculture, with about 76 percent of artificial milk ventures using precision fermentation. Few pursue mammary cell culture, and the ones listed are at research stage.
Cost levers are clear. Replace prolactin and other costly growth factors with cheaper hormone combinations, raise cell density and secretion rates, reuse or recycle medium, and move from planar culture to perfusion or microcarrier systems. Each lever affects regulatory documentation as well, because changes in the medium or the cells need re-evaluation.
Because of the cost, early products are likely to be components, not bulk milk. High-value proteins, lipids or oligosaccharides can justify a high unit cost, while a litre of drinking milk cannot. For ingredient buyers, this suggests watching cell-cultured components that complement precision-fermented lactoferrin and similar bioactives before expecting commodity milk.
Regulatory status of cell-cultured milk
No approval for a cell-cultured milk product appears in the regulatory sources reviewed here. Singapore’s list of approved novel foods dated 14 August 2026 includes cultured chicken, Japanese quail, duck and a beef steak, plus animal-free beta-lactoglobulin from fermentation, but no entry for mammary cell milk. The same list is the best map of what regulators have processed.
In the United States, food made from cultured animal cells goes through a voluntary FDA pre-market consultation that evaluates the cell line, banking, manufacturing controls and all inputs. The inventory of completed consultations lists chicken cell material, pork fat cell material and salmon cell material, with no mammary cell or milk product among the entries shown.
In the EU, food produced from cell cultures is a novel food and requires EFSA assessment and a Union list entry. Companies planning a launch should engage regulators early, define the cell line and medium precisely and prepare allergen and composition data as part of the dossier before any sale can begin.
Labelling will be a separate question. Milk is a major allergen, so a product that contains casein or whey proteins must declare milk. Naming rules for dairy terms also differ by market, and cell-based products may not be allowed to use terms reserved for milk from animals. Companies should check descriptor rules before choosing a name.
Nutrition, function and applications
Nutritional performance cannot be assumed. Cell-cultured milk will contain only the components the cells secrete in the chosen medium, which may include proteins, lipids and lactose in proportions that differ from cow’s milk. A full amino acid, fat and mineral analysis is needed, along with testing of functional behaviour in cheese, yogurt and beverages.
Hybrid products are one early application. Wilk announced in December 2022 a yoghurt made with cell-cultured milk fat, which it described as the first of its kind. The company stated that external laboratories validated the product against the required chemical and biological criteria, and that it was presented to selected members of the Israeli public for tasting rather than sold.
The likely first uses are ingredient niches. Components such as milk proteins, fats or bioactive proteins could be added to blended dairy and plant-based products. The mammary gland-on-a-chip work focuses on selected human milk components, which points to infant nutrition and bioactive ingredients as targets, subject to a long safety review.
Cheesemaking and yogurt need caseins, which require correct phosphorylation and micelle assembly. Mammalian cells carry the Fam20C kinase that phosphorylates caseins, which is a point in favour of the cell route over microbial hosts. The fermentation route is described in precision fermentation casein, including the phosphorylation problem in detail there too.
Sensory properties are still undefined. Flavour will depend on the fat, lactose and protein secreted by the cells, and on the processing applied afterwards. Developers should treat any early sample as a prototype ingredient and run bench trials for heat stability, foaming, coagulation and flavour before considering a commercial formulation.
Comparison with other dairy alternatives
Compared with plant-based milks, cell-cultured milk offers real milk components and a closer match to animal milk, but at much higher cost and with no commercial approvals in the sources reviewed. Compared with precision fermentation, it can produce a richer mixture of components, while fermentation offers lower cost and more mature scale-up.
For product developers, the practical advice is to track the regulatory map and the cost curve, and to use established ingredients today. Precision-fermented whey proteins and plant proteins are available now, while cell-based milk is a research and pilot topic that may supply high-value components first, as costs fall and approvals appear.